Stockhub

ARYx Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 August 2022

11 August 2022

3 August 2022

  • curprev 05:4505:45, 3 August 2022‎ Chris talk contribs‎ 1,295 bytes +1,295‎ Created page with "ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clot..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/ARYx_Therapeutics,_Inc.’